PharmaCyte Biotech Inc Financial Flexibility Index
PharmaCyte Biotech Inc financial flexibility index. PharmaCyte Biotech Inc (PMCB) has a Financial Flexibility Index of -0.12x as of April 2026. Free cash flow of $-1.39 Million (operating CF $-1.39 Million minus capex $0.00) represents 0% of total liabilities ($11.77 Million). See PharmaCyte Biotech Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of PharmaCyte Biotech Inc (2002–2026)
Financial flexibility index of PharmaCyte Biotech Inc from 2002 to 2026. Historical Financial Flexibility Index trend for PharmaCyte Biotech Inc across 25 annual periods. Check PMCB operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
PharmaCyte Biotech Inc Financial Flexibility Index by Year (2002–2026)
PharmaCyte Biotech Inc financial flexibility index by year from 2002 to 2026. Year-by-year free cash flow to debt coverage for PharmaCyte Biotech Inc. For the full cash flow conversion analysis, see PMCB cash flow metrics.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2026 | -0.44x | $-5.15 Million | $-5.15 Million | $11.77 Million | ▲ +51.8% |
| 2025 | -0.91x | $-2.98 Million | $-2.98 Million | $3.28 Million | ▼ -761.2% |
| 2024 | -0.11x | $-2.15 Million | $-2.15 Million | $20.39 Million | ▲ +98.4% |
| 2023 | -6.47x | $-3.79 Million | $-3.79 Million | $586.58K | ▼ -10.6% |
| 2022 | -5.85x | $-4.12 Million | $-4.12 Million | $704.37K | ▼ -27.2% |
| 2021 | -4.60x | $-3.33 Million | $-3.33 Million | $724.78K | ▼ -111.8% |
| 2020 | -2.17x | $-2.34 Million | $-2.34 Million | $1.08 Million | ▲ +44.0% |
| 2019 | -3.87x | $-2.88 Million | $-2.88 Million | $742.85K | ▲ +50.9% |
| 2018 | -7.89x | $-5.08 Million | $-5.08 Million | $644.17K | ▼ -37.0% |
| 2017 | -5.76x | $-3.34 Million | $-3.34 Million | $580.25K | ▲ +15.6% |
| 2016 | -6.82x | $-4.35 Million | $-4.35 Million | $637.64K | ▼ -200.8% |
| 2015 | -2.27x | $-4.56 Million | $-4.56 Million | $2.01 Million | ▼ -143.7% |
| 2014 | 5.18x | $1.94 Million | $-1.56 Million | $373.67K | ▲ +5144.3% |
| 2013 | -0.10x | $-390.43K | $-390.43K | $3.80 Million | ▼ -50.1% |
| 2012 | -0.07x | $-259.29K | $-259.29K | $3.79 Million | ▼ -23.4% |
| 2011 | -0.06x | $-220.15K | $-225.23K | $3.97 Million | ▲ +82.0% |
| 2010 | -0.31x | $-974.06K | $-974.06K | $3.15 Million | ▲ +23.7% |
| 2009 | -0.40x | $-1.18 Million | $-1.19 Million | $2.92 Million | ▲ +93.8% |
| 2008 | -6.48x | $-1.17 Million | $-1.19 Million | $180.56K | ▼ -323.2% |
| 2007 | 2.90x | $344.92K | $-351.60K | $118.81K | ▲ +297.3% |
| 2006 | -1.47x | $-1.06 Million | $-1.07 Million | $723.89K | ▲ +12.0% |
| 2005 | -1.67x | $-2.73 Million | $-2.80 Million | $1.63 Million | ▼ -212.5% |
| 2004 | -0.53x | $-176.03K | $-221.03K | $329.13K | ▲ +96.4% |
| 2003 | -14.84x | $-37.46K | $-37.46K | $2.52K | ▼ -429.9% |
| 2002 | -2.80x | $-21.99K | $-21.99K | $7.86K | — |